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Abstract: Calciphylaxis is a disabling and life-threatening complication that primarily affects 
patients who are dialysis dependent. Reports have grown in the literature of cases occurring in 
those who have advanced chronic kidney disease (pre-end-stage renal disease) or in the setting 
of transplantation. There are also a few reports of cases occurring in those without any form of 
chronic kidney disease but with primary hyperparathyroidism. This disease entity is characterized 
by calcification, intimal hypertrophy, and thrombosis of small vessels that result in necrotizing, 
nonhealing ulcers – many of which are life threatening. Although several strategies aimed at 
treating and preventing this affliction have been reported in the literature, the outcome for most 
patients with calciphylaxis remains quite poor. We describe a patient with comparatively early 
stage-3 chronic kidney disease who developed calciphylaxis in the setting of both primary and 
secondary hyperparathyroidism. Predictably, after subtotal parathyroidectomy, her wounds did 
not completely heal and her biochemical markers of hyperparathyroidism did not completely 
normalize until her underlying secondary hyperparathyroidism was treated medically. It was only 
after initiating cinacalcet that the patient experienced complete wound healing and resolution of 
her calciphylaxis. It also supports other authors’ findings that cinacalcet may be an important 
adjunct in the treatment of calciphylaxis.
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Case report
A 66-year-old Caucasian woman with a medical history significant for chronic kidney 
disease (CKD) stage 3, hypertension, and morbid obesity was followed regularly at 
our nephrology and hypertension clinic. She was being treated aggressively for her 
hypertension, proteinuria, hyperuricemia, and secondary hyperparathyroidism (SHPT). 
Her baseline creatinine fluctuated between 1.5 mg/dL and 2.0 mg/dL, and eGFR 
(6 variable Modification of Diet in Renal Disease) between 24 and 34 mL/min/1.73 m2. 
Her home medications included paricalcitol, gemfibrozil, febuxostat, pantoprazole, 
furosemide, lisinopril, latanoprost ophthalmic, and ferrous sulfate. Our patient had 
never taken warfarin, vitamin D, or any oral phosphate binders. In 2009, her intact 
parathyroid hormone (PTH) levels were noted to be rising despite her receiving oral 
paricalcitol 1 mcg daily. The dose was eventually adjusted up to 2 mcg daily without 
controlling her PTH which climbed as high as 216 pg/mL. Her calcium levels climbed 
from 9.0 to 10.4 mg/dL but never higher. Her serum phosphorous levels ranged from 
2.9 to 3.7 mg/dL before, during, and after subsequent treatment. Most importantly, 
the Ca2+ × PO4
2- solubility product was never greater than 33.7. In August 2010, she 
presented with painful eruptions and ulcerations along the medial aspects of her thighs 
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and intertriginous spaces of the lower extremities, slightly 
more on her right side. Initially, our patient was concerned 
that it represented a drug-related exanthem in response to a 
newly initiated uric acid-lowering agent. Accordingly, she 
had tried to self-medicate using over-the-counter preparations 
without success. Eventually she sought medical attention.
On exam, the presence of violaceous ulcerations were 
identified along the aforementioned distributions, some of 
which had already begun to drain purulent material. She was 
prescribed oral doxycycline as well as Cleocin-T gel and 
cultures and biopsy were procured while at the dermatology 
clinic. The patient was not noted to have had any substantial 
changes in her weight. An extensive hypercoagulable workup 
was negative, as was the presence of antiphospholipid 
  antibodies. Complement levels were normal but serum pro-
tein electrophoresis found elevation of acute phase reactants 
suggesting acute inflammation. Cultures were unrevealing, 
however, the biopsy from the right medial thigh lesion 
revealed dermal necrosis with severe neutrophilic inflamma-
tion of the local blood vessels. The biopsy was nonspecific 
as calcium deposition was not identified, but the clinical 
picture was strongly suggestive of calciphylaxis. A repeat 
biopsy was not obtained due to our fear of inciting another 
ulcerating lesion. Furthermore, it has been shown that der-
matopathology is most often nonspecific and often needs to 
be repeated several times to see the typical microvascular 
calcifications associated with calciphylaxis.1 For this reason, 
our nephrology clinic generally does not recommend biopsy 
of these ulcers.
At this point she was sent for a three-phase technetium 
bone scan that was markedly abnormal on blood pool imaging 
(Figure 1). It demonstrated widespread hyperintensities in 
the soft tissue of her thighs bilaterally corresponding to the 
suspect lesions, once again more so on her right side. The use 
of this imaging modality in calciphylaxis has been reported 
numerous times and has been shown to be abnormal with 
soft tissue uptake in up to 97% of patients with calciphylaxis, 
whether ulcerating or not.1,2 As such, she was referred for a 
technetium sestamibi parathyroid scan, which was suspicious 
for a parathyroid adenoma on the lower pole of the left lobe 
of the thyroid. This scan was repeated and confirmed by our 
surgeon who then performed a subtotal parathyroidectomy 
the following day. Intraoperatively, an enlarged parathyroid 
gland was identified, corresponding to the abnormality seen 
on imaging. It was later confirmed to be a hyperplastic para-
thyroid adenoma by pathology.
In the weeks following surgery, the drainage from her 
wounds begun to wane, margins began to heal, and her PTH 
level fell to 136 pg/mL, though did not fall lower on serial 
follow-up. It was at this point that her primary hyperparathy-
roidism was consider to have been definitively been treated, 
but the patient’s “background” SHPT had not. We were 
reluctant to give her oral vitamin D, or vitamin D   receptor 
antagonists; instead, she was given cinacalcet. Within 
3 months, her PTH had fallen to 38 pg/mL and her wounds 
had entirely healed.
Administration of the cinacalcet was not associated with 
hypocalcemia or significant change to our patient’s Ca2+ × PO4
2- 
solubility product, which was low to begin with.
Discussion
Calciphylaxis (often referred to as calcific uremic arteri-
olopathy) is a disabling, and potentially life-threatening 
complication that has been reported to affect as many as 
4% of patients with end-stage renal disease.3 It has been 
observed to occur primarily in patients receiving maintenance 
hemodialysis and peritoneal dialysis. However, syndromes 
resembling calciphylaxis have been reported in individuals 
with pre-end-stage renal disease-staged CKD and even more 
rarely in those without any evidence of renal dysfunction but 
with inflammatory bowel disease, malignancy, trauma, and 
primary hyperparathyroidism.4–7
This disease entity is characterized by calcification, inti-
mal hypertrophy, and thrombosis of small vessels that slowly 
lead to tissue ischemia followed by infarction. Predominantly 
affecting subcutaneous tissue, this   microvasculopathic 
Figure 1 White arrows indicate areas of amorphous hyperintensity seen in the 
soft tissue on blood pool imaging of the 3-phase bone scan. They correspond to the 
patient’s calciphylactic ulcers.
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  process leads to the formation of painful nodules or plaques, 
which are often described as erythematous or violaceous 
foci that later erupt as necrotizing, nonhealing ulcers. These 
lesions are typically distributed in highly vascular regions 
with thick overlying adipose tissue such as the breast, 
  abdomen, and thighs, although acral and even visceral organ 
involvement has been reported.4 The formation of these 
ulcerating necrotic lesions portends a grim prognosis as they 
are often accompanied by severe infectious complications 
resulting in mortality rates that can exceed 60%.3,8
Several strategies aimed at treating and preventing this 
affliction in the nondialysis population have been reported 
in the literature. These include early parathyroidectomy,5,7 
sodium thiosulfate,8,9 vitamin D analogs,9 bisphosphonates,10 
cinacalcet,10,11 and hyperbaric oxygen.12 Unfortunately, 
none of these maneuvers have been shown to be universally 
beneficial and the outcome for most patients afflicted with 
calciphylaxis remains quite poor.
We describe a unique case of a patient with stage 3 
CKD who presented with calciphylaxis when she developed 
primary hyperparathyroidism superimposed on background 
SHPT that was actively being treated with paricalcitol. She 
developed her lesions in the face of escalating dosages of 
the vitamin D analog despite normal Ca2+ × PO4
2- solubility 
products. What is interesting in this case is that her wounds 
did not begin to heal until her parathyroid adenoma was 
surgically removed and did not completely heal until her 
PTH level was normalized with cinacalcet.
PTH disrupts calcium homeostasis. In primary disease 
this is demonstrated in a straightforward way as PTH is 
secreted in a constitutive fashion from the parathyroid cells 
without regard for ambient serum calcium levels, often driv-
ing the remaining parathyroid glands into dormancy in the 
process. Hypercalcemia and/or high Ca2+ × PO4
2- solubility 
products subsequently develop. In secondary disease the 
pathway is more complex.
In CKD, the kidney has a decreased ability to generate 
1,25-dihydroxycholecalciferol (calcitriol) from its precur-
sor ergocalciferol via the kidney 25(OH) 1-α-hydroxylase 
enzyme. Phosphate retention gradually occurs and this, in 
conjunction with reduced calcitriol levels, results in reduced 
intestinal calcium absorption and decreased serum calcium 
levels. As the degree of CKD progresses, the cellular expres-
sion of vitamin D receptors and calcium-sensing receptors 
(CaSRs) decrease within the parathyroid cells. Furthermore, 
the CaSRs are less sensitized to ambient calcium levels.13,14 
These circumstances eventually lead to an increase in 
PTH release and a resultant rise in calcium levels. In the 
  long-term, this phenomenon is maladaptive as it leads to bone 
  demineralization (renal osteodystrophy). In these scenarios, 
PTH is believed by some investigators to enhance coronary 
artery calcifications15 and lead to the aforementioned micro-
vascular calcification, intimal hypertrophy, and thrombosis, 
which in turn leads to ischemia and subsequent calciphylactic 
ulcers.16 More recently, fibroblast growth factor 23 (FGF-23) 
has been established as an important player in the regulation 
of phosphate-vitamin D homeostasis. FGF-23 concentration 
increases in CKD and contributes to the development of SHPT. 
Elevations in FGF-23 expression lead to the downregulation 
of residual renal 25(OH) 1-α-hydroxylase enzyme activity. 
This unfortunately potentiates the previously mentioned 
deficiency of calcitriol production, resulting in enhanced PTH 
synthesis and subsequent parathyroid hyperplasia.17
In our patient, both pathways were operating   concurrently. 
It also explains why she had an excellent initial response to a sur-
gical intervention in the form of a subtotal   parathyroidectomy. 
As the parathyroid adenoma was removed, her PTH levels fell. 
However, it was not until the calcimimetic agent cinacalcet 
was added that the PTH level normalized followed by com-
plete wound healing. Calcimimetic agents activate the CaSRs, 
thereby potentiating the effects of ambient extracellular 
  calcium on parathyroid cell function.18 This, in effect, reen-
gages a negative feedback loop and suppresses PTH secretion. 
Calcimimetics also upregulate CaSR- and vitamin D-receptor 
expression and, in animal models, reduce parathyroid gland 
hypertrophy.19 In our patient, the use of cinacalcet allowed 
us to lower her secondary elevations in PTH without having 
to provide her with calcitriol or vitamin D analogs, which 
theoretically may have worsened her calciphylaxis.
In conclusion, calciphylaxis is a disabling and   potentially 
life-threatening complication most often accompany-
ing advanced degrees of renal insufficiency. A variety of 
interventions have been proposed to treat and/or prevent 
this morbid condition; unfortunately, the outcome for most 
patients afflicted with calciphylaxis remains poor. To the 
best of our knowledge, this case represents the first reported 
case of an individual with stage 3 CKD who developed cal-
ciphylaxis amidst mixed hyperparathyroidism (both primary 
and secondary) and was successfully treated with subtotal 
parathyroidectomy (for pathologically confirmed parathyroid 
adenoma) followed by cinacalcet (for background SHPT). 
We feel this case is extraordinary because of the patient’s 
development of calciphylaxis in spite of her relatively 
mild stage of CKD, as well as clinical response to specific 
therapy targeted at the pathophysiology of both primary and 
SHPT as detailed. Based on our experience in conjunction 
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with that reported by others, we feel that administration of 
  calcimimetics should be considered as an important adjunct 
in the treatment of calciphylaxis.
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